Topic: Ovarian cancer: are biopsy practice changes required?
Proudly supported by AstraZenecaMonday February 26 | 7:00-8:00pm AEDT
Ovarian cancer treatment has experienced recent advancements through precision medicine. Radiologists involved in the collection of biopsies for ovarian cancer diagnosis play an important role in obtaining sufficient tissue for standard of care genomic testing used to guide these new therapies.
Learn from Dr Nick Brown and Dr Yeh Chen Lee as they discuss why and how to improve core biopsy sample quality for genomic testing to support optimal outcomes for advanced ovarian cancer patients.
Meet our guest speakers and meeting chair:Dr Nick Brown: Meeting Chair
Dr Brown is a specialist Interventional Radiologist, with particular interests in interventional oncology, health economics, thoracic interventions and urologic interventions. A graduate of the University of Queensland, Dr Brown undertook radiology training at The Royal Brisbane and Women’s Hospital and a fellowship in Interventional Radiology at St Vincent’s Hospital Melbourne. He gained further post-graduate qualifications in Sports Medicine from the University of Queensland, an MPhil in Bioscience Enterprise from the University of Cambridge, and a Master of Public Health (Epidemiology) from Harvard University. He is also certified by the European Board of Interventional Radiology (EBIR).
Dr Brown is Clinical Director of Radiology at The Wesley Hospital, a Senior Staff Specialist Radiologist at The Prince Charles Hospital and Chair of the RANZCR Interventional Radiology Committee.
Dr Yeh Chen Lee
Dr Yeh Chen Lee is a clinical researcher and medical oncologist with subspecialty expertise in gynaecological cancers and soft tissue sarcoma. Dr Lee is a Staff Specialist at the Prince of Wales – Royal Hospital for Women; and a Research Fellow at the NHMRC Clinical Trials Centre, University of Sydney.
Dr Lee’s research focus is to improve patient cancer care, through advancing and translating knowledge in cancer genetics, drug development and supportive care. Dr Lee is highly active in clinical trials in gynaecological cancers and holds leadership position as the chair of the NGOR (National Gynae-Oncology Registry) rare cancer group, tumour group committee member at ANZGOG (Australia New Zealand Gynaecological Oncology Group), and Gynaecological Cancer Reference Committee member for EviQ Cancer Treatment Online. She is also the scientific advisory committee member for ANZSA (Australia New Zealand Sarcoma Association).
Dr Lee’s qualifications and publications can be found on this link: https://orcid.org/0000-0003-2009-8263